Characteristics of the randomized controlled clinical trials included in this analysis.

I, DPP-4 inhibitor group; C, control group; NA, not applicable; NR, not reported; HD, hemodialysis; PD, peritoneal dialysis; eGFR, estimated glomerular filtration rate; SBT, stable background therapy. *For studies that used placebo as the comparison group for the first period of time (12 weeks) and sulfonylureas for an extended 40–42 weeks, only data from the first period were extracted for the meta-analyses. #Only data for subjects with moderate to severe renal impairment in this trial were extracted for analysis. Characteristics of the randomized controlled clinical trials included in this analysis.